1. Ketamine for the treatment of Refractory Status Epilepticus 2. Heterogeneity of Leucine-Rich Repeat Kinase 2 Mutations: Genetics, Mechanisms, and Therapeutic Implications 3. Glioblastoma: Treatment Challenges and Future Directions."

Dates and Times

Start: 6/7/2019 8:00 AM
End: 6/7/2019 9:00 AM

Objectives

1) The basics for early rational polypharmacotherapy and
neuroprotective strategies in Status Epilepticus. 2) Intravenous
Ketamine Infusion: Challenges and Opportunities.3) Current guidelines
to use IV Ketamine for Refractory Status Epilepticus at Stony Brook
Hospital: the QA Project.

2) Mutations in LRRK2 is the most
common genetic cause of Parkison's disease. 2.0Mechanisms of these
mutations are heterogeneous which implicate diverse therapeutic
approaches for patients with different LRRK2 mutations.

3) 1. Understanding the current state of GBM therapies. 2. Understanding treatment challenges and resistance.3.Understanding new and potential therapies currently being investigated

4) Title- Heterogeneity of Leucine-Rich Repeat Kinase 2 Mutations: Genetics, Mechanisms, and Therapeutic Implications. Mutations in LRRK2 is the most common genetic cause of Parkison's disease. Mechanisms of these mutations are heterogeneous which implicate diverse therapeutic approaches for patients with different LRRK2 mutations.

5)Title-Fetal Surgery for Spina Bifida. Understand differences in outcomes between patients who have received fetal vs postnatal surgery for closure of myelomeningocele. Understand potential complications & risks of fetal surgery for myelomeningocele

6)Title- When is it safe to start Anti-coagulation after an Acute Ischemic Stroke? This talk will cover current literature looking at when is it considered safe to start AC and then review data from Stony Brook. The talk will end with an overview of current multi-center clinical trials that are currently enrolling patients in order to answer this question.